Bull Harbor Capital LLC Makes New Investment in Merck & Co., Inc. $MRK

Key Points

• Bull Harbor Capital LLC initiated a position in Merck during the first quarter, purchasing 23,691 shares valued at approximately $2.85 million, representing 0.8% of its portfolio.
• Institutional ownership remains substantial at 76.07%, with major investors including Norges Bank, Wellington Management, Cardano Risk Management, Jennison Associates and T. Rowe Price adjusting or adding to their positions.
• Merck has a generally favorable outlook, supported by positive analyst targets and encouraging KEYTRUDA trial results, but analysts expect second-quarter earnings to decline. The company also declared a quarterly dividend of $0.85 per share, yielding about 2.6% annually.

Bull Harbor Capital LLC bought a new position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund bought 23,691 shares of the company's stock, valued at approximately $2,850,000. Merck & Co., Inc. accounts for approximately 0.8% of Bull Harbor Capital LLC's holdings, making the stock its 16th biggest holding.

A number of other hedge funds have also modified their holdings of the company. Norges Bank acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $3,997,933,000. Wellington Management Group LLP lifted its holdings in Merck & Co., Inc. by 14.8% during the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company's stock worth $9,098,196,000 after acquiring an additional 11,156,354 shares in the last quarter. Cardano Risk Management B.V. acquired a new position in Merck & Co., Inc. in the fourth quarter valued at about $1,012,530,000. Jennison Associates LLC bought a new stake in shares of Merck & Co., Inc. in the fourth quarter worth about $585,192,000. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Merck & Co., Inc. by 37.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company's stock worth $1,973,983,000 after purchasing an additional 5,152,069 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Barclays raised its price target to $150 from $140 and maintained an “overweight” rating, implying roughly 15% upside from the referenced price. The increase reflects continued confidence in Merck’s outlook. Barclays raises Merck price target
• Positive Sentiment: KEYTRUDA met its primary progression-free-survival endpoint in a Phase 3 trial for advanced or recurrent endometrial cancer, outperforming platinum-based chemotherapy. Merck said the result could support future regulatory filings and strengthen its oncology pipeline. Merck KEYTRUDA endometrial cancer trial
• Positive Sentiment: Merck announced its fourth-quarter 2026 dividend, reinforcing the stock’s appeal to income-oriented investors and signaling continued capital-return support. The provided announcement did not include the dividend amount or payment details. Merck fourth-quarter dividend announcement
• Neutral Sentiment: Wells Fargo reiterated its Buy rating, while broader brokerage coverage places Merck at a “Moderate Buy” consensus, indicating generally favorable but not universally bullish sentiment. Wells Fargo maintains Merck Buy rating
• Negative Sentiment: Analysts expect Merck’s second-quarter earnings to decline, and a Zacks preview says the company lacks the typical signals associated with a likely earnings beat. This raises near-term execution risk ahead of the earnings report. Merck second-quarter earnings preview

Merck & Co., Inc. Stock Down 1.0%

Shares of Merck & Co., Inc. stock opened at $130.45 on Thursday. The business's 50 day simple moving average is $122.73 and its 200 day simple moving average is $118.24. Merck & Co., Inc. has a 52-week low of $77.53 and a 52-week high of $135.05. The firm has a market cap of $322.18 billion, a PE ratio of 36.75, a P/E/G ratio of 5.23 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping analysts' consensus estimates of ($1.47) by $0.19. The firm had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business's revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.22 EPS. On average, analysts predict that Merck & Co., Inc. will post 2.74 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.'s payout ratio is currently 95.77%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Cantor Fitzgerald reiterated a "neutral" rating and issued a $120.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Weiss Ratings lowered shares of Merck & Co., Inc. from a "hold (c+)" rating to a "hold (c)" rating in a research note on Friday, May 15th. Bank of America upped their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a "buy" rating in a report on Tuesday, June 30th. UBS Group increased their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a research report on Monday, April 13th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an "overweight" rating in a report on Monday, July 13th. Thirteen equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $134.50.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source